Approval sought to repurpose Hepatitis C drug for COVID-19 in India | Inquirer News

Approval sought to repurpose Hepatitis C drug for COVID-19 in India

/ 01:04 PM April 05, 2021

Approval sought to repurpose Hepatitis C drug for COVID-19 in India

FILE PHOTO: A healthcare worker collects a coronavirus disease (COVID-19) test swab sample from a man as others watch, at a temporary shelter for the homeless in New Delhi, India, March 31, 2021. REUTERS/Adnan Abidi/File Photo

BENGALURU — India’s Cadila Healthcare Ltd has sought approval from local regulators to use a Hepatitis C drug as a treatment for COVID-19 following promising interim results from a late-stage trial, the drugmaker said on Monday.

A single dose of the Hepatitis C drug when taken early could help COVID-19 patients recover faster and avoid complications seen in the advanced stages of the disease, Cadila said in a statement to stock exchanges.

Article continues after this advertisement

About 91% of patients treated with the drug tested negative for COVID-19 in standard RT-PCR tests by day seven, compared to nearly 79% who were given the standard of care, the company said citing Phase-III clinical trial data.

FEATURED STORIES

The drug, known as Pegylated Interferon alpha-2b and branded as ‘PegiHep’ by Cadila, was originally approved for liver disease Hepatitis C and launched in India 10 years ago. It is being repurposed to treat COVID-19.

The news comes as daily coronavirus infections are surging to new highs in India, which has the world’s third-highest caseload after the United States and Brazil. India has so far reported close to 12.5 million infections and more than 164,000 deaths.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: COVID-19, hepatitis C, India

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.